Search

Search results

Berlin Cures initiates Phase I study with novel treatment against heart failure

Berlin Cures, one of Ascenion’s investment portfolio companies, has announced the start of a clinical trial with its lead candidate BC007. The Phase I study comprises two parts involving healthy volunteers and elderly, autoantibody-positive individuals who are otherwise also healthy. The goal is to evaluate the candidate’s safety, tolerability, pharmacokinetics and efficacy in man.

BC007 represents a new, causal treatment approach to heart failure, a condition which affects around 1.8 million people in Germany alone. It is the first candidate from the company’s proprietary platform of aptamers: short oligonucleotide chains that bind highly specifically to autoantibodies directed against G-protein-coupled receptors, removing them from the patient’s blood. As shown by scientists at the Max Delbrück Center for Molecular Medicine and the Charité during many years of research, these antibodies are implicated in the development of many common diseases.

For further information: News Berlin Cures